Condensed Interim Consolidated Financial Statements of:

Unidoc Health Corp.
For the three and nine months ended December 31, 2023 and 2022

Expressed in Canadian Dollars

NOTE TO READER

Under National Instrument 51-102, if an auditor has not performed a review of interim financial statements, they must be accompanied by a note indicating that the interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements have been prepared by and are the responsibility of management. The Company's independent auditor has not performed a review of these interim financial statements.

Unidoc Health Corp.
Condensed Interim Consolidated Statements of Financial Position
(Expressed in Canadian dollars)

As at	Note		December 31, 2023 (Unaudited)		March 31, 2023 (Audited)
ASSETS					
Current					
Cash		$	81,584	$	51,323
Prepaid expenses and deposits			74,518		884
Inventory			19,329		-
Receivables			133,811		80,128
			309,242		132,335
Equipment	5		139,525		128,001
Right-of-use asset	6		34,053		57,628
Security deposits			2,501		2,503
TOTAL ASSETS		**$**	**485,321**	**$**	**320,467**
LIABILITIES AND EQUITY					
Current					
Accounts payable and accrued liabilities	7,10	$	1,778,257	$	1,126,462
Loans payable	9,10		38,243		12,482
Lease liability	8		31,000		28,148
			1,847,500		1,167,092
Loans payable	9,10		13,216		27,775
Lease liability	8		2,768		26,388
TOTAL LIABILITIES			1,863,484		1,221,255
Equity					
Share capital	11		3,380,229		2,762,655
Reserves	11		1,313,744		935,887
Deficit			(6,072,136)		(4,599,330)
			(1,378,163)		(900,788)
TOTAL LIABILITIES AND EQUITY		**$**	**485,321**	**$**	**320,467**

Going concern (Note 2)

Approved on behalf of the Board of Directors on February 29, 2024:

"Antonio Baldassarre" (signed)
Director

"Franco Staino" (signed)
Director

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

(Unaudited - Expressed in Canadian dollars)

		Three months ended December 31,		Nine months ended December 31,	
	Note	**2023**	**2022**	**2023**	**2022**
EXPENSES					
Advertising		$ 2,328	$ 4,640	$ 184,065	$ 156,976
Consulting	10	143,225	118,372	431,986	393,469
Depreciation	5,6	27,006	15,543	68,178	46,199
Foreign exchange (gain)/loss		(2,690)	22,661	(8,357)	22,252
Interest expense	8,9	2,076	2,110	6,894	6,919
Office and administrative		36,551	19,667	96,835	71,298
Professional fees		51,119	12,138	130,725	85,211
Regulatory and filing fees		10,820	6,823	28,045	15,220
Research and development	10	-	-	-	12,091
Salaries and benefits		41,227	22,364	84,416	69,653
Share-based compensation	10,11	-	-	380,386	-
Shipping and delivery		8,942	-	8,942	-
Software		-	155	-	549
Travel and entertainment		21,935	7,895	60,691	51,747
NET LOSS AND COMPREHENSIVE LOSS		$ 342,539	$ 232,368	$ 1,472,806	$ 931,584
Weighted average number of shares outstanding - basic and diluted		13,673,657	10,933,350	12,215,751	10,933,350
Loss per share - Basic and diluted		$ (0.02)	$ (0.02)	$ (0.12)	$ (0.09)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

(Unaudited - Expressed in Canadian dollars)

	Number of common shares		Share capital		Reserves		Deficit		Total equity
Balance, March 31, 2022	10,933,350	$	2,762,655	$	935,887	$	(3,242,266)	$	456,276
Net loss	-		-		-		(931,584)		(931,584)
Balance, December 31, 2022	**10,933,350**	**$**	**2,762,655**	**$**	**935,887**	**$**	**(4,173,850)**	**$**	**(475,308)**
Balance, March 31, 2023	10,933,350	$	2,762,655	$	935,887	$	(4,599,330)	$	(900,788)
Exercise of unit warrants	2,747,100		508,199		(2,529)		-		505,670
Exercise of warrants	-		109,375		-		-		109,375
Grant of options	-		-		380,386		-		380,386
Net loss	-		-		-		(1,472,806)		(1,472,806)
Balance, December 31, 2023	**13,680,450**	**$**	**3,380,229**	**$**	**1,313,744**	**$**	**(6,072,136)**	**$**	**(1,378,163)**

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Unidoc Health Corp.
Condensed Interim Consolidated Statement of Cash Flows
(Unaudited - Expressed in Canadian dollars)

		Nine months ended December 31, 2023		Nine months ended December 31, 2022
OPERATING ACTIVITIES				
Net loss	$	(1,472,806)	$	(931,584)
Non-cash items:				
Depreciation		68,176		46,199
Interest expense		2,483		-
Share-based compensation		380,386		-
Changes in non-cash working capital:				
Receivables		(53,681)		(9,695)
Prepaid expenses and deposits		(73,634)		4,918
Inventory		(19,329)		
Accounts payable and accrued liabilities		595,670		163,246
Cash used in operating activities		**(572,735)**		**(726,916)**
INVESTING ACTIVITIES				
Purchase of equipment		-		(16,962)
Cash used in investing activities		**-**		**(16,962)**
FINANCING ACTIVITIES				
Cash proceeds from exercise of $0.50 warrants		109,375		-
Cash proceeds from exercise of unit warrants		505,670		-
Cash proceeds from the issuance of loan		20,000		-
Repayment of loans		(11,281)		-
Lease liability payments		(20,768)		(18,261)
Cash provided by (used in) financing activities		**602,946**		**(18,261)**
NET CHANGE IN CASH		30,261		(762,139)
CASH, BEGINNING		51,323		854,430
CASH, ENDING	**$**	**81,584**	**$**	**92,291**
SUPPLEMENTAL CASH FLOW INFORMATION				
Income taxes paid	$	-	$	-
Interest paid	$	6,894	$	-
Equipment additions in accounts payable and accrued liabilities	$	56,125	$	17,725

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

1. NATURE OF BUSINESS

Unidoc Health Corp. (the "Company") was incorporated under the Business Corporations Act of British Columbia on February 1, 2021 as Unicheck Holdings Corp. and changed its name to Unidoc Health Corp. on April 8, 2021. Unicheck Holdings Corp., a wholly-owned subsidiary of the Company, was incorporated under the Business Corporations Act of British Columbia on April 8, 2021.

The Company operates in the healthcare services industry and plans to operate telehealth units which contain fully integrated diagnostic tools and will provide patients with the ability to have a live virtual visit with a doctor or other health professional. The Company trades on the Canadian Securities Exchange ("CSE") under the symbol UDOC.

The registered office of the Company is located at 750 Pender Street West, Suite 1200 Vancouver, British Columbia V6C 2T7, Canada. The head office of the Company is located at 81 Zenway Blvd. Unit 18 Woodbridge, Ontario L4H 0S5.

2. GOING CONCERN

These condensed interim consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern which assumes the Company will be able to continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations.

The Company has not generated any revenues or cash flows from operations and relies on financing for its activities. During the nine months ended December 31, 2023, the Company incurred a net loss of $1,472,806 and, as at December 31, 2023, the Company's current liabilities exceeded its current assets by $1,538,258. The Company's ability to continue as a going concern is dependent upon raising additional capital or evaluating strategic alternatives. These factors indicate the existence of material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

These condensed interim consolidated financial statements do not reflect adjustments that would be necessary if the going concern assumption was not appropriate. If the going concern assumption was not appropriate for these financial statements, adjustments would be necessary to the statement of financial position classifications used. Such adjustments could be material.

These condensed interim consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes that the Company will be able to realize its assets and satisfy its liabilities in the normal course of business for the foreseeable future.

3. BASIS OF PRESENTATION

Statement of Compliance

These unaudited condensed interim consolidated financial statements have been prepared in accordance with IAS 34 – Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"). Accordingly, certain disclosures included in annual financial statements prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the IASB have been condensed or omitted and these unaudited condensed interim consolidated financial statements should be read in conjunction with the Company's audited financial statements for the year ended March 31, 2023.

The Company's management makes judgments in its process of applying the Company's accounting policies in the preparation of its unaudited condensed interim consolidated financial statements. In addition, the preparation of the financial data requires that the Company's management make assumptions and estimates of the effects of uncertain future events on the carrying amounts of the Company's assets and liabilities at the end of the reporting period and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates as the estimation process is inherently uncertain. Estimates are reviewed on an ongoing basis based on historical experience and other factors that are considered to be relevant under the circumstances. Revisions to estimates and the resulting effects on the carrying amounts of the Company's assets and liabilities are accounted for prospectively. The critical judgments and estimates applied in the preparation of the Company's unaudited condensed interim consolidated financial statements are consistent with those applied and disclosed in the Company's financial statements for the year ended March 31, 2023. The accounting policies applied in these unaudited condensed interim consolidated financial statements are consistent with those applied and disclosed in the Company's audited financial statements for the year ended March 31, 2023. During the nine months ended December 31, 2023, the Company adopted additional significant accounting policies as follows:

Inventory

Inventory is valued at the lower of cost and net realizable value. The Company accounts for inventory using the specific identification method. Inventory costs include acquisition costs and other costs incurred to bring inventories to their present location and condition. If the Company determines that the estimated net realizable value of its inventory is less than the carrying value of such inventory, it records a charge to cost of sales.

The Company's interim results are not necessarily indicative of its results for a full year.

Basis of Presentation

These condensed interim consolidated financial statements have been prepared on a historical cost basis and presented in Canadian dollars which is the functional currency of the Company. The financial statements of the Company have been prepared on an accrual basis, except for cash flow information. The condensed interim consolidated financial statements have been prepared on a historical cost basis except for warrants and options, which are measured at fair value.

3. BASIS OF PRESENTATION (CONTINUED)

Basis of Consolidation

These condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Subsidiaries are those entities over which the Company has control. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity and be exposed to variable returns from its activities. Details of the Company's subsidiary are follows:

SUBSIDIARIES	OWNERSHIP PERCENTAGE	JURISDICTION OF INCORPORATION
Unicheck Holdings Corp.	100%	British Columbia, Canada

Inter-company balances and transactions are eliminated on consolidation.

Comparative Figures

Certain comparative figures have been reclassified to conform with the basis of presentation applied for the nine months ended December 31, 2023. These reclassifications had no effect on the reported results of operations or cash flow.

4. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Financial Instruments

The Company's financial instruments are comprised of cash, receivables, accounts payable and accrued liabilities and its loans payable. Fair values of financial instruments are classified in a fair value hierarchy based on the inputs used to determine fair values. The levels of the fair value hierarchy are as follows:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly (i.e. as prices) or indirectly (i.e. derived from prices);
Level 3 - Inputs that are not based on observable market data (unobservable inputs).

As at December 31, 2023 the fair value of cash held by the Company was based on Level 1 of the fair value hierarchy. The fair values of receivables, accounts payable and accrued liabilities, and loan payable approximate their carrying values due to their short-term maturity.

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Credit risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. The Company's credit risk is primarily attributable to its cash. The Company limits exposure to credit risk by maintaining its cash with large financial institutions. The Company does not have cash that is invested in asset backed commercial paper. Credit risk is not concentrated with any particular customer. The Company's receivables consist of GST receivable.

(Unaudited - Expressed in Canadian Dollars)

4. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (CONTINUED)

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company seeks to ensure there is sufficient capital in order to meet short-term business requirements, after taking into account cash flows from operations and the Company's holdings of cash. As at December 31, 2023, the Company had a cash balance of $81,584 to settle current liabilities of $1,820,882. Historically, the Company's sources of funding has been through equity financings. The Company's access to financing is uncertain. There can be no assurance of continued access to significant debt or equity funding.

		Within one year		Between one and five years		More than five years
Accounts payable and accrued liabilities	$	1,778,257	$	-	$	-
Loan payable		38,243		13,216		-
Lease liability		31,000		2,768		-
	$	1,847,500	$	15,984	$	-

5. EQUIPMENT

The Company's demonstration units include four medical cart demonstration units and two urgent care demonstration units. The intention of these units is to demonstrate the effectiveness of the Company's virtual care solutions model in order to generate future sales. The units are sent to prospective customers for demonstration purposes and are not intended for sale.

		Medical cart and urgent care demonstration units		Computer equipment		Total
Cost						
Balance, March 31, 2022	$	66,272	$	26,746	$	93,018
Additions		69,465		8,317		77,782
Balance, March 31, 2023		135,737		35,063		170,800
Additions		56,125		-		56,125
Balance, December 31, 2023	$	191,862	$	35,063	$	226,925
Accumulated depreciation						
Balance, March 31, 2022	$	5,700	$	4,309	$	10,009
Depreciation		18,376		14,414		32,790
Balance, March 31, 2023		24,076		18,723		42,799
Depreciation		32,698		11,903		44,601
Balance, December 31, 2023	$	56,774	$	30,626	$	87,400
Net book value						
March 31, 2023	**$**	**111,661**	**$**	**16,340**	**$**	**128,001**
December 31, 2023	**$**	**135,088**	**$**	**4,437**	**$**	**139,525**

(Unaudited - Expressed in Canadian Dollars)

6. RIGHT-OF-USE ASSET

During the year ended March 31, 2022, the Company entered into a lease agreement to lease an office space for an initial term of 36 months (Note 8). The lease commenced on February 1, 2022 and the related right-of-use asset was recorded.

		Building
Cost		
Balance, March 31, 2022	$	94,301
Additions		-
Balance, March 31, 2023 and December 31, 2023	$	94,301
Accumulated depreciation		
Balance, March 31, 2022	$	5,239
Depreciation		31,434
Balance, March 31, 2023		36,673
Depreciation		23,575
Balance, December 31, 2023	$	60,248
Net book value		
Balance, March 31, 2023	**$**	**57,628**
Balance, December 31, 2023	**$**	**34,053**

7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

		December 31, 2023		**March 31, 2023**
Accounts payable	$	1,478,281	$	833,657
Accrued liabilities		299,976		292,805
Total	**$**	**1,778,257**	**$**	**1,126,462**

8. LEASE LIABILITY

During the year ended March 31, 2022, the Company entered into a lease agreement to lease an office space for an initial term of 36 months. The expiry date of the lease is January 1, 2025. Upon expiration, the Company is entitled to renew the lease for an additional 36 month term on written notice of not less than 6 months prior to expiry of the initial term. Additional payments consisting of utilities and additional rent are expensed as incurred. The lease commenced on February 1, 2022 and the related lease liability was recorded.

(Unaudited - Expressed in Canadian Dollars)

8. LEASE LIABILITY (CONTINUED)

		Building
Lease liability		
Balance, March 31, 2022	$	79,286
Interest expense		8,823
Lease payments		(33,573)
Balance, March 31, 2023		54,536
Interest expense		4,411
Lease payments		(25,179)
Balance, December 31, 2023	**$**	**33,768**
Current portion	**$**	**31,000**
Long-term portion	**$**	**2,768**
	$	**33,768**

At December 31, 2023, the Company is committed to minimum lease payments as follows:

Maturity analysis		
Less than one year	$	33,573
One to five years		2,798
Total undiscounted lease liabilities	**$**	**36,371**

9. LOANS PAYABLE

On February 28, 2023, the Company's Chief Executive Officer (the "CEO") took out a $40,000 loan through his personal credit card for the Company's working capital purposes. The loan bears interest of 7.99% annually and is due in 36 months.

On June 28, 2023, the Company received an additional loan of $20,000. The loan bears interest at 7.30% compounded annually and is due on demand.

The continuity of loans payable for the nine months ended December 31, 2023 and year ended March 31, 2023 is summarized below:

		Loans Payable
Balance, March 31, 2022	$	-
Additions		40,000
Interest expense		257
Balance, March 31, 2023	$	40,257
Additions		20,000
Interest expense		2,483
Loan payments		(11,281)
Balance, December 31, 2023	**$**	**51,459**
Current portion	**$**	**38,243**
Long-term portion	**$**	**13,216**
	$	**51,459**

(Unaudited - Expressed in Canadian Dollars)

10. RELATED PARTY TRANSACTIONS

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company's executive officers and Board of Director members.

All related party transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments.

a) Related party transactions with directors, subsequent and former directors and companies and entities over which they have significant influence over:

	Three months ended December 31, 2023	Three months ended December 31, 2022	Nine months ended December 31, 2023	Nine months ended December 31, 2022
Consulting (i)	$ 54,682	$ 39,774	$ 161,960	$ 131,896
Research and development (i)	$ -	$ -	$ -	$ 12,091
Share-based compensation (ii)	$ -	$ -	$ 46,086	$ -

(i) To a company controlled by a director of the Company.
(ii) To directors of the Company.

b) Key management compensation

	Three months ended December 31, 2023	Three months ended December 31, 2022	Nine months ended December 31, 2023	Nine months ended December 31, 2022
Consulting (iii)	$ 60,000	$ 49,998	$ 180,000	$ 149,994
Share-based compensation (iv)	$ -	$ -	$ 97,489	$ -

(iii) To a company controlled by the CEO.
(iv) To the CEO and CFO.

As at December 31, 2023, accounts payable and accrued liabilities included $331,571 (March 31, 2023 - $110,882) due to a company controlled by the CEO of the Company, $118,985 (March 31, 2023 - $74,546) due to the CEO of the Company and $618,770 (March 31, 2023 - $350,137) due to a company controlled by a director of the Company. The balances due bear no interest, are unsecured, and are due on demand.

As at December 31, 2023, loans payable included $31,072 (March 31, 2023 - $40,257) which was drawn from the CEO of the Company's personal credit card (Note 9).

11. EQUITY

(a) Share Capital

Authorized

Unlimited number of common shares without par value.

Issued

For the nine months ended December 31, 2023:

During the nine months ended December 31, 2023, 2,528,350 warrants (the "Unit Warrants") were exercised for 2,528,350 units at an exercise price of $0.20 per unit, for total proceeds of $505,670. Each unit consisted of one common share and one additional common share purchase warrant (the "Additional Warrant"). Each Additional Warrant is exercisable at $0.50 per share with an expiry date of December 13, 2024.

During the nine months ended December 31, 2023, 218,750 Additional Warrants were exercised for 218,750 common shares at an exercise price of $0.50 per share, for total proceeds of $109.375.

For the nine months ended December 31, 2022:

There was no share capital activity during the nine months ended December 31, 2022.

Escrow

Pursuant to an escrow agreement dated June 24, 2021 (the "NP 46-201 Escrow Agreement") among the Company, Odyssey Trust Company as escrow agent, and certain principals of the Company, 2,200,000 common shares and 250,000 stock options were deposited into escrow. 10% of the escrowed securities were released on the date the Company's common shares were listed for trading on the CSE, which was December 13, 2021 (the "Listing Date") and the remaining escrowed securities are scheduled for release in 15% tranches every six months thereafter.

An aggregate of 7,200,000 common shares are subject to voluntary resale restrictions ("Voluntary Resale Restrictions") pursuant to which 10% of such shares will be released on the date that is 12 months after the Listing Date with the remaining shares being released in 15% tranches every four months thereafter.

In addition, an aggregate of 15,000,000 Unit Warrants (including underlying securities) were subject to escrow pursuant to which 25% of the Unit Warrants were released on the Listing Date, and the remaining Unit Warrants will be released in 25% tranches every six months thereafter.

As of the date hereof, 175,000 stock options have been released from the NP 46-201 Escrow Agreement and 15,000,000 Unit Warrants have been released from escrow. 1,540,000 common shares have been released from the NP 46-201 Escrow Agreement. 3,240,000 common shares remain subject to Voluntary Resale Restrictions.

(Unaudited - Expressed in Canadian Dollars)

11. EQUITY (CONTINUED)

(b) Warrants

The continuity of warrants for the nine months ended December 31, 2023 and year ended March 31, 2023 is summarized below:

	Number of warrants		Weighted average exercise price	Weighted average life remaining
Balance, March 31, 2022	2,522,507	$	1.67	1.24
Issued	-		-	-
Balance, March 31, 2023	2,522,507		1.67	0.99
Expired	(165,207)		1.75	N/A
Exercised	(218,750)		0.50	N/A
Issued	2,528,350		0.50	0.95
Balance, December 31, 2023	4,666,900	$	1.09	1.50

As at December 31, 2023, the number of warrants outstanding and exercisable are as follows:

Number of warrants		Price	Expiry date
1,376,050	$	2.50	October 25, 2026
3,290,850	$	0.50	December 13, 2024

(b) Unit Warrants

The continuity of Unit Warrants for the nine months ended December 31, 2023 and year ended March 31, 2023 is summarized below:

	Number of warrants		Weighted average exercise price	Weighted average life remaining
Balance, March 31, 2022	14,018,750	$	0.20	2.71
Exercised	-		-	-
Balance, March 31, 2023	14,018,750		0.20	1.71
Exercised	(2,528,350)		0.20	N/A
Balance, December 31, 2023	11,490,400	$	0.20	0.95

Options

On September 28, 2023, the Company finalized its new Omnibus Equity Incentive Plan (the "Plan"), which will replace the existing stock option plan. The Plan provides that the Board of Directors of the Company may from time to time, in its discretion, grant to directors, officers, employees and technical consultants and contractors to the Company, equity incentive awards in the form of stock options, restricted share units, share appreciation rights, deferred share units, and performance share units.

(Unaudited - Expressed in Canadian Dollars)

11. EQUITY (CONTINUED)

All equity incentives granted pursuant to the Plan shall be subject to the terms and conditions of the Plan. The number of shares which will be available for purchase pursuant to an option will be equal to the number of shares as determined by the Board of Directors from time to time, provided that the number of common shares reserved for issuance will not exceed 20% of the issued and outstanding common shares. If any option expires or otherwise terminates for any reason without having been exercised in full, the number of shares in respect of such expired or terminated option shall again be available for the purposes of granting options pursuant to the Plan.

The grant date and the expiry date of an option shall be the dates fixed by the Board of Directors at the time the option is granted and shall be set out in the option certificate issued in respect of such option. The exercise price shall also be determined by the Board of Directors and set out in the option certificate issued in respect of the option. If the Company's shares are listed on a stock exchange, the exercise price will not be lower than the greater of the last closing price for the shares as quoted on the trading day prior to the grant date and the grant date.

On June 26, 2023, the Company issued 1,073,000 stock options exercisable at $0.60 for a period of 2 years to officers, directors and consultants. The stock options vested immediately. The fair value of the options of $380,386 was determined by using the Black-Scholes Options Pricing model with the following weighted average assumptions: a 2 year expected life; share price at the grant date of $0.57, 122.58% volatility; risk-free interest rate of 4.61%; and a dividend yield of 0%.

Total share-based compensation expense for the nine months ended December 31, 2023 was $380,386 (2022 - $Nil).

The continuity of stock options for the nine months ended December 31, 2023 and the year ended March 31, 2023 is summarized below:

	Options Outstanding		Weighted average exercise price		Weighted average fair value	Weighted average life remaining
Balance, March 31, 2022	960,000	$	0.86	$	0.39	1.37
Exercised	-		-		-	-
Balance, March 31, 2023	960,000		0.86		0.39	0.37
Granted	1,073,000		0.60		0.35	1.49
Expired	(520,000)		0.50		0.26	N/A
Cancelled	(440,000)		1.25		0.53	N/A
Balance, December 31, 2023	1,073,000	$	0.60	$	0.35	1.49

The following table discloses the number of options outstanding as at December 31, 2023:

Number of options		Price per share	Expiry date	Number of options vested
1,073,000	$	0.60	June 26, 2025	1,073,000
1,073,000				1,073,000

(Unaudited - Expressed in Canadian Dollars)

12. SEGMENTED INFORMATION

The Company has one operating segment, being the provider of telehealth units.

As at December 31, 2023 and March 31, 2023, the Company's equipment were located as follows:

		December 31, 2023		March 31, 2023
Canada	$	41,813	$	16,341
USA		28,607		61,646
United Arab Emirates		42,254		50,014
Italy		26,853		-
Total	**$**	**139,525**	**$**	**128,001**

13. COMMITMENTS

The Company entered into a consulting agreement dated effective February 24, 2021 with a company controlled by the CEO and is committed to the following fee structure for the next three years:

- $15,000 per month for the first year of service;
- $16,667 per month for the second year of service; and
- $20,000 per month for the third year of service.

Notwithstanding the above, the consulting fees will increase to $25,000 per month once the Company has earned a profit.

The agreement has a three-year term which may be terminated by the company controlled by the CEO with a lump sum cash severance payment equal to 18 months of such company's aggregate monthly consulting fee currently in effect at the effective date of termination, subject to a minimum monthly consulting fee rate equal to $16,667. If the agreement terminated for cause, the foregoing severance will not be payable.

The Company entered into a consulting agreement dated effective February 28, 2021 with a company controlled by a director of the Company and is committed to the following fee structure for the next three years:

- US$10,000 per month for the first year of service;
- US$11,667 per month the second year of service; and
- US$13,333 per month for the third year of service. Notwithstanding the above, the consulting fees will increase to US$15,000 per month once the Company has earned a profit.

The Company has the right to terminate the agreement at any time for a lump sum severance payment of 18 months of the monthly consulting fee in effect at the time of termination subject to a minimum monthly consulting fee rate equal to US$11,667.

14. CAPITAL MANAGEMENT

The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of equity which is comprised of issued share capital and deficit.

The Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board of Directors, will balance its overall capital structure through new share issues or by undertaking other activities as deemed appropriate under the specific circumstances.

The Company is not subject to externally imposed capital requirements as at December 31, 2023. There was no change to the Company's approach to capital management during the nine months ended December 31, 2023.